Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Dr. Reddy’s enters into licensing agreement with Gilead Sciences for HIV drug
Additionally, Lenacapavir is currently under investigation for the prevention of HIV (PrEP) which is yet to be approved globally.
Dr Reddy's, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir
Dr Reddy's Laboratories and Hetero, along with other generic drug makers, enter into voluntary licensing agreements with Gilead Sciences to produce and distribute HIV drug Lenacapavir in India and 120 LMICs.
Dr. Reddy’s and Hetero join hands with Gilead to broaden access to HIV drug Lenacapavir in low-income countries
Dr. Reddy’s and Hetero partner with Gilead Sciences to manufacture and distribute Lenacapavir for HIV treatment in LMICs.
Dr. Reddy’s Secures Licensing Deal with Gilead for Lenacapavir in 120 Countries
The drug is currently approved for treating heavily treatment-experienced (HTE) adults with multi-drug resistant HIV.
Dr Reddy’s, Hetero ink royalty-free pact with Gilead
Dr Reddy's Laboratories and Hetero sign non-exclusive, royalty-free agreements with Gilead Sciences to manufacture Lenacapavir for HIV treatment in India and 120 LMICs, enhancing access for heavily treatment-experienced adults.
Dr. Reddy's inks licensing pact with Gilead to commercialise HIV drug
Lenacapavir is a US Food and Drug Administration (FDA) approved medication indicated for the treatment of HIV type 1 (HIV-1) infection in heavily treatment-experienced adults facing multi-drug resistant HIV-1.
Dr. Reddy’s, Hetero ink deal with Gilead to make, market generic HIV drug lenacapavir
Dr. Reddy's, Hetero, and Mylan partner with Gilead to manufacture generic lenacapavir for HIV prevention in 120 countries.
Dr Reddy's, Hetero sign voluntary licenses with Gilead for HIV drug
Gilead Sciences first launched lenacapavir under the brand name Sunlenca in the United States and European markets in 2022. It is a first-in-class HIV-1 capsid inhibitor
Daily
2h
Dr Reddy's Labs arm Chirotech Technology dissolves
Hyderabad: Dr Reddy's Labs has informed in a BSE filing that Chirotech Technology Limited, UK a step down wholly owned ...
3h
Dr. Reddy's Laboratories Share Price Live Updates: Dr. Reddy's Laboratories shows steady growth
Stay up-to-date with the Dr. Reddy's Laboratories Stock Liveblog, your trusted source for real-time updates and thorough ...
moneycontrol.com
7h
Dr Reddy’s enters pact with Gilead Sciences to manufacture, sell HIV drug Lenacapavir in India and 120 countries
Dr
Reddy
’s Laboratories said it has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead ...
2d
on MSN
Dr Reddy's completes acquisition of UK co Haleon's non-US nicotine replacement therapy biz
Hyderabad-based pharma giant Dr Reddy’s Ltd finalizes its largest acquisition by buying British Haleon Plc’s non-US nicotine ...
2h
ITC, Dr Reddy's, Tata Steel, JSW Steel, other stocks in action today
Here is a list of stocks that are set to be in focus during Thursday's session, as participants return to trade after a day's ...
13d
Dr. Reddy's Laboratories Share Price Today Updates: Dr. Reddy's Laboratories Sees Minor Daily Decline Amid Positive Six-Month Returns
Welcome to the Dr. Reddy's Laboratories Stock Liveblog, your ultimate source for real-time updates and analysis of one of the ...
newsmeter
1d
Hyderabad: LV Prasad Eye Hospital doctor Nilay Reddy dies in car accident at ORR
Hyderabad: Dr. Nilay Reddy, a senior doctor at LV Prasad Eye Hospital, was killed in a fatal road accident near Himayathsagar ...
money.rediff
2d
Dr Reddy's Acquires Haleon's NRT Portfolio
Dr Reddy's Laboratories has completed the acquisition of Haleon plc's global Nicotine Replacement Therapy (NRT) portfolio, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback